Study Summary
This trial is testing a drug to treat KRAS-mutated cancer, including lung, pancreatic and colon cancer.
- KRAS Mutation-Related Tumors
- Colorectal Cancer
- Pancreatic Cancer
- Recurrent Cancer
- Refractory Cancer
- Stage IV Colorectal Cancer
- Non-Small Cell Lung Cancer (Stage IV)
- Stage III Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage III Colorectal Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 3 Secondary · Reporting Duration: 46 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Escalation Phase
1 of 2
Expansion Phase
1 of 2
Experimental Treatment
90 Total Participants · 2 Treatment Groups
Primary Treatment: Escalation Phase · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
In what geographic locations can prospective participants access this trial?
"Patients are being accepted to participate at Roswell Park Cancer Institute in Buffalo, New York; NEXT Oncology in San Antonio, Texas; Fred Hutch, University of Washington in Seattle, California and a couple other sites." - Anonymous Online Contributor
Has the Escalation Phase received regulatory approval from the FDA?
"Due to the fledgling nature of Escalation Phase, our team has rated its safety at a 1. This is due to limited data supporting both efficacy and security checks." - Anonymous Online Contributor
Is this examination still accepting new participants?
"The records hosted on clinicaltrials.gov suggest that this trial, first published on December 1st 2022 and last updated November 20th 2022, is no longer in need of participants. However, there are still 3686 other medical studies currently open for enrolment." - Anonymous Online Contributor